STATCenter·
STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study
A closely watched cardiovascular drug from Novartis failed in a pivotal study, the company said Friday, a major blow to the firm.
Read at STAT →
Health · 1 sources covering this
STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study
A closely watched cardiovascular drug from Novartis failed in a pivotal study, the company said Friday, a major blow to the firm.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/ec2fdb7b22d51b287b7f095ee0817a0180018e1c" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study"></iframe>